Vonoprazan

Vonoprazan
Clinical data
Trade names	Voquezna, others
AHFS/Drugs.com	Voquezna
MedlinePlus	a624006
License data	US DailyMed: Vonoprazan;
Routes of; administration	By mouth
Drug class	Potassium-competitive acid blocker
ATC code	A02BC08 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Unknown
Protein binding	80%
Metabolism	Liver, by cytochrome P450 (3A4, 2B6, 2C19, 2D6)
Elimination half-life	7.7 h
Duration of action	> 24 h
Excretion	Kidney
Identifiers
CAS Number	881681-00-1; as fumarate: 1260141-27-2;
PubChem CID	15981397; as fumarate: 45375887;
DrugBank	DB11739;
ChemSpider	13112797;
UNII	1R5L3J156G; as fumarate: 4QW3X4AMLB;
KEGG	D11784; as fumarate: D10466;
ChEBI	CHEBI:136048;
ChEMBL	ChEMBL2079130; as fumarate: ChEMBL2064032;
PDB ligand	HKT (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID20236869 ;
Chemical and physical data
Formula	C17H16FN3O2S
Molar mass	345.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccccc1-c2cc(CNC)cn2S(=O)(=O)c3cccnc3;
	InChI InChI=InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3; Key:BFDBKMOZYNOTPK-UHFFFAOYSA-N;

Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.

It was approved in Japan in February 2015, and in Russia in April 2021. Vonoprazan was approved for medical use in the United States in November 2023. Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available.